ADC 下一代 — 载荷创新
zanidatamab 新辅助 · 无化疗 pCR 30%，HER2 下调 56%
我们在 Her2 靶向治疗方面取得了重大进展，尤其是一线治疗。我们的 Jaffer Ajani 博士在 #AACR26 上分享了相关内容。Zanidatamab/tislelizumab/化疗可能用于 Her2 阳性胃食管腺癌患者，无论其 PDL-1 状态如何。#EndCancer
热度 17 · 13 赞 · 0 回复 · 4 转发
Ankur Karmokar, Emanuele Loro, Al Hassan Kyakulaga, Desmond Lau, Nina Weisser, Genevieve Desjardins, Prajwal Raghunatha, Edwin Clark, Robin Humphreys, Kedar S. Vaidya
读摘要原文 →Vicente Valero, Paula R. Pohlmann, Jason Mouabbi, Xuelin Huang, Wei Qiao, Heather R. Alonzo, Rashmi Krishna Murthy, Gaiane M. Rauch, Taiwo Adesoye, Cristina M. Checka, William F. Symmans, Dmitri Grachev, Flora Alajajyan, Adaeze Nwosu-Iheme, Amy Hassan, Miral Mahesh Patel, Sharon H. Giordano, Kelly Hunt, Debasish Tripathy, Funda Meric-Bernstam
读摘要原文 →Vivek Subbiah, Vicky Makker, Do-Youn Oh, Elizabeth Gardener, Elaina Gartner, Funda Meric-Bernstam
读摘要原文 →来源：UT MD Anderson · x.com